(Circulation. 1997;96:4095-4103.)
© 1997 American Heart Association, Inc.
Articles |
Roles of Infectious Agents in Atherosclerosis and Restenosis1
An Assessment of the Evidence and Need for Future Research
From Brigham and Women's Hospital, Harvard Medical School, Boston, Mass (P.L.), and the National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Md (D.E., S.S.).
Correspondence to Peter Libby, MD, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, 221 Longwood Ave, Boston, MA 02115. E-mail plibby{at}bustoff.bwh.harvard.edu
Key Words: endothelium • leukocytes • muscle, smooth • risk factors • viruses
 |
Introduction |
|---|
 Top Introduction Evidence Supporting Involvement...ChlamydiaChlamydiaHerpesviridae, Including CMV...Direct Infection of Cultured...Effects of Infection and...The Weight of the...On Transfer to a...Unanswered Questions and Areas...Summary and AssessmentReferences |
|---|
The past few years have witnessed a resurgence of interest in the possibility that infectious processes may contribute to arterial diseases, including atherosclerosis and restenosis after arterial intervention. The recent recognition that Helicobacter pylori contributes to peptic ulcers illustrates how a disease previously believed to result primarily from excessive gastric acid production often involves a microbial pathogen. Although hypercholesterolemia clearly predisposes to development of coronary heart disease, many patients with arterial pathology have serum cholesterol levels within or below the average range. Coronary heart disease frequently affects individuals who lack other traditional risk factors as well. These findings suggest that heretofore unrecognized risk factors may also contribute to the pathogenesis of coronary heart disease.
At a recent Special Emphasis Panel convened by the National Heart, Lung, and Blood Institute, a number of experts reviewed the evidence for links between infectious processes and atherosclerosis and restenosis. This report will summarize and examine critically the evidence for involvement of infectious agents in arterial diseases based on the deliberations of this expert panel. It will also highlight some of the unanswered questions in this area that may warrant further investigation.
Many reports of associations between a wide variety of infectious agents and atherosclerosis have recently appeared. An exhaustive evaluation of each of these purported associations lies beyond the scope of this survey. Rather, we will concentrate particularly on two particular infectious agents, one viral and one bacterial, currently linked with atherogenesis and supported by emerging evidence. Specifically, this report will focus primarily on herpesviruses, particularly cytomegalovirus (CMV), as an example of a viral agent and Chlamydia pneumoniae (C pneumoniae, also known as the TWAR strain on the basis of its original laboratory designation) as an example of a bacterial pathogen. Although the preponderance of recent studies have examined CMV and Chlamydia, the focus of this report on these more fully developed examples in no way excludes the possibility that similar principles may apply to other infectious agents.
|
Evidence Supporting Involvement of Infectious Agents in Atherosclerosis and Restenosis |
|---|
|
TopIntroductionEvidence Supporting Involvement...ChlamydiaChlamydiaHerpesviridae, Including CMV...Direct Infection of Cultured...Effects of Infection and...The Weight of the...On Transfer to a...Unanswered Questions and Areas...Summary and AssessmentReferences |
|---|
Seroepidemiological Evidence (Table
)Herpesviridae, Including CMV
The herpesvirus family includes three groups of human pathogens, the herpesvirus hominis family, currently known to contain more than half a dozen members; CMV; and the Epstein-Barr virus. Systematic studies have linked antibodies to CMV and atherosclerosis for many years. Pioneering examples include the studies from Melnick's group.1,2 These authors performed case-control studies on patients undergoing cardiovascular surgery and those lacking evidence of atherosclerotic disease. High titers of CMV antibodies were more frequent in patients undergoing surgery for atherosclerotic disease (70%) than in matched control patients (43%).2 In that study, there was no significant difference in the titers of antibodies directed against the herpesvirus hominis type I or type II. In addition, a case-control study performed on a subset of the Atherosclerosis Risk in Communities (ARIC) study documented a significant difference between carotid artery intimal thickening (determined by B-mode ultrasound) and the level of anti-CMV antibodies.3 There was no correlation with antibodies directed against Herpes simplex virus type 1 or type 2 antigens. The association with CMV antibody titers did not depend on traditional cardiovascular risk factors. A subsequent prospective study in the ARIC cohort confirmed this relationship.4
|
In the realm of restenosis after coronary interventional therapy, recent evidence suggests an association between previous CMV infection and restenosis. Quantitative coronary arteriography documented a greater reduction in minimum luminal diameter at the sites of coronary atherectomy in patients seropositive for CMV than in seronegative patients.5 According to the criteria established by these investigators, 43% of seropositive versus 8% of seronegative patients developed angiographically definable restenosis (P<.002). Interestingly, the risk for restenosis correlated with IgG antibody rather than IgM antibody, and IgG levels did not vary between the primary intervention and follow-up angiogram, indicating prior infection rather than acute CMV infection as the risk factor for restenosis.
In the special case of accelerated arteriosclerosis
developing in the coronary arteries of transplanted hearts,
some seroepidemiological evidence also suggests an association with CMV
infection. In the Stanford experience, cardiac transplant recipients
who developed CMV infection, determined by a fourfold rise in IgG
antibody, more frequently developed angiographically detectable graft
arteriosclerosis than did patients without
serological evidence of CMV infection.6 At 6 years after
transplantation, the actuarial rate of development of >70% luminal
narrowing was <10% in the patients without evidence for CMV infection
versus 
30% for those with evidence for CMV infection
(P<.05). Independent studies from other centers have also
linked CMV infection with transplantation
arteriosclerosis.7–9
The foregoing examples provide evidence for a potential association between CMV infection and arterial disease. However, not all such studies support an association between CMV and allograft arteriosclerosis.10 Such discrepancies point to some of the challenges of interpreting such seroepidemiological studies. Because infections with Herpesviridae, including CMV, are very common, many individuals in the general population will exhibit antibody titers suggestive of prior infection with these agents, including CMV. Conversely, many patients with documented arterial diseases will lack high titers of antibodies directed against these viruses. Thus, these data do not prove a causal relationship between infection with these viruses and arterial diseases.
Other limitations of these seroepidemiological studies include the relatively small numbers of patients enrolled in studies at any one center. Issues regarding the specificity and sensitivity of the antibody techniques used apply in such surveys. Often, the agents and methods used vary from center to center, making it difficult to compile the results obtained in various studies to increase the power of the analysis. Moreover, a bias exists against publication of negative studies, which may favor appearance in the literature of positive reports.
|
Chlamydia |
|---|
|
TopIntroductionEvidence Supporting Involvement...ChlamydiaChlamydiaHerpesviridae, Including CMV...Direct Infection of Cultured...Effects of Infection and...The Weight of the...On Transfer to a...Unanswered Questions and Areas...Summary and AssessmentReferences |
|---|
Chlamydia are Gram-negative bacteria. Three species cause human disease: (1) C trachomatis, which causes sexually transmitted disease and eye disease such as trachoma; (2) C psittaci, which infects birds and causes a human pneumonitis; and (3) C pneumoniae, which causes upper respiratory infections. Recent seroepidemiological studies support a relationship between prior infection with C pneumoniae and atherosclerosis. Originally, small observational studies established that patients with acute myocardial infarction or chronic coronary artery disease had higher titers of chlamydial antigens than did control patients.11 Blood samples that had been collected prospectively in the course of the Helsinki Heart Study hinted at a relationship between antichlamydial IgA or immune complexes containing lipopolysaccharide from Chlamydia and the development of acute myocardial infarction.12 These studies prompted independent efforts to correlate seroepidemiological manifestations of chlamydial disease with atherosclerosis by use of a nested case-control design.13,14
The various seroepidemiological studies correlating various serological indexes of chlamydial infection with atherosclerosis have been for the most part descriptive (eg, cross-sectional) rather than analytical (eg, with a prospective cohort or case-control design). For this reason, the literature to date suffices to suggest hypotheses but cannot establish a causal relationship. A publication bias favoring positive studies must be taken into account when the existing database is evaluated. Moreover, descriptive studies generally do not control for certain confounding variables. For example, smoking, a risk factor for coronary heart disease events, may predispose to C pneumoniae infection and contribute to elevated titers of antibody to this organism.15
Studies Localizing Infectious Agents to Human Arterial
Lesions (Table
)
Herpesviridae, Including CMV
Despite attempts over many decades, it has been difficult to
culture Herpesviridae from human atheroma.2
However, failure to culture infectious virus particles from the lesions
does not preclude their involvement in aspects of the pathogenesis of
the disease. There are well-documented instances of "hit-and-run"
mechanisms of herpes-mediated disease in which the viruses trigger the
disease without persisting in an infectious form in the affected
tissue.16 Indeed, a variety of subsequent studies from many
centers have documented the presence of CMV or herpes simplex virus,
nucleic acid, and/or antigen in human atheroma (reviewed in
Reference 22 ). Landmark studies along these lines include demonstration
of herpes simplex virus nucleic acid sequences in human intimal lesions
by Benditt et al17 and work from Bruggeman's laboratory
that showed more frequent detection of CMV genomic DNA by polymerase
chain reaction amplification in atherosclerotic specimens than in
nonatherosclerotic arteries.18 Interestingly, the
prevalence of detection of CMV genome by this technique exceeded 50%
in the uninvolved arteries, compared with 90% in
atheromatous vessels, showing considerable overlap in
nonatherosclerotic and atherosclerotic specimens. Direct DNA blotting
analysis of these same specimens showed CMV DNA in 50% of
either atherosclerotic or uninvolved arteries. CMV nucleic acids have
also been localized in coronary
arteriosclerotic lesions in transplanted
hearts.19 Attempts to recover CMV RNA transcripts from
human atherosclerotic specimens, however, have proved
unsuccessful.20 In contrast, CMV DNA is commonly found in
the human arterial tree.21,22
|
Chlamydia |
|---|
|
TopIntroductionEvidence Supporting Involvement...ChlamydiaChlamydiaHerpesviridae, Including CMV...Direct Infection of Cultured...Effects of Infection and...The Weight of the...On Transfer to a...Unanswered Questions and Areas...Summary and AssessmentReferences |
|---|
Several recent studies have furnished evidence for the presence of Chlamydia in human atherosclerotic specimens.23,24 A variety of techniques, including immunocytochemistry, polymerase chain reaction detection of nucleic acid, electron microscopy, and culture support the presence of Chlamydia in various stages of atheromatous disease in a variety of human arteries.25–28 A recent prospective study from the Utah group using immunofluorescence detected chlamydial antigen in 79% of 90 coronary atherectomy specimens but found antigen in only 1 of 24 nonatherosclerotic coronary specimens (
4%).29 The recovery of these organisms by culture,
however, has been much less successful.30
Evidence for Presence of Other Infectious Agents in Human
Arterial Lesions
As noted above, over the years many individual potential pathogens
have been implicated in the pathogenesis of
atherosclerosis. Sporadic reports of the presence of
such organisms in atheroma exist. A notable recent addition
to the list of potential pathogens includes Helicobacter
species.31
Animal Studies Implicating Infectious Agents in
Atherosclerosis
|
Herpesviridae, Including CMV (Table)
|
|---|
|
TopIntroductionEvidence Supporting Involvement...ChlamydiaChlamydiaHerpesviridae, Including CMV...Direct Infection of Cultured...Effects of Infection and...The Weight of the...On Transfer to a...Unanswered Questions and Areas...Summary and AssessmentReferences |
|---|
The firmest scientific foundation linking an infectious agent with chronic arterial disease is the case of Marek's disease in chickens. This avian herpesvirus causes epidemic lymphoproliferative disease in chickens. Infection of specific-pathogen–free chickens with the Marek's disease virus produced arterial lesions.32 Moreover, with concomitant consumption of a cholesterol-enriched diet, the Marek's disease-infected birds developed fibrofatty lesions sharing certain characteristics of human atherosclerosis. Subsequent studies in Japanese quail demonstrated the presence of sequences related to Marek's disease virus genome in the lesions of Japanese quail genetically susceptible to atherosclerosis, whereas relatively resistant strains lacked such sequences.33,34 No infectious virions were recovered from these quail lesions, however.
CMV infection enhances the neointimal response to balloon injury in rats. Moreover, in experimental heart transplantation in rats, infection with rat CMV causes subendothelial inflammation, endothelial activation (defined by class II major histocompatibility antigen expression), and increased intimal thickening and promotes the development of allograft arteriosclerosis.35,36
Animal Evidence Linking Chlamydia With
Arterial Disease (Table)
The published literature contains only minimal data supporting a
role for C pneumoniae infection in animal models of
atherosclerosis. Repeated inoculation of genetically
hyperlipidemic rabbits (the Watanabe strain) has
resulted in lung abnormalities but no alteration in the aortic
atherosclerosis that develops in this
strain.37 Moreover, attempts to isolate C
pneumoniae and immunocytochemical detection of chlamydial antigen
or polymerase chain reaction evidence for chlamydial nucleic acid in
the aorta were unrevealing. After intranasal infection of mice with
C pneumoniae, detection of organisms was much more frequent
in the atheromatous aortas of
atherosclerosis-susceptible apolipoprotein E–deficient
mice than in the aortas of wild type strains.38
Possible Pathophysiological Mechanisms of
Infectious Agents in Atherosclerosis and
Restenosis Based on In Vitro Observations
|
Direct Infection of Cultured Cells |
|---|
|
TopIntroductionEvidence Supporting Involvement...ChlamydiaChlamydiaHerpesviridae, Including CMV...Direct Infection of Cultured...Effects of Infection and...The Weight of the...On Transfer to a...Unanswered Questions and Areas...Summary and AssessmentReferences |
|---|
Herpesviridae, including CMV. A large body of experimental evidence shows that human vascular wall cells, including smooth muscle cells and endothelium, can be infected by Herpesviridae, including CMV.39,40 CMV can also infect human endothelial cells and alter functions related to atherosclerosis, such as the procoagulant balance of the endothelium.41–43
Chlamydial infection of cells involved in atherogenesis.C pneumoniae, an obligate intracellular parasite, commonly infects mononuclear phagocytes. Macrophages, derived from monocytes, characteristically localize in human atherosclerotic plaques. Data regarding the biology of Chlamydia infection of vascular smooth muscle and endothelial cells are scant.44 However, Chlamydia species can infect epithelial cells persistently under certain conditions. Under normal circumstances, the life cycle of Chlamydia involves two developmental forms, the elementary body and the replicative form, the reticulate body. Treatment of the continuous cell line HeLa 229 with the cytokine gamma interferon renders these cells susceptible to a persistent infection with C trachomatis.45–47 Thus, infection with Chlamydia need not result in a lethal infection but may cause a chronic persistent and nonlytic infection of cells. The susceptibility of macrophages and vascular wall cells to persistent infection by C pneumoniae remains unknown.
|
Effects of Infection and Microbial Products on Vascular Cell Functions |
|---|
|
TopIntroductionEvidence Supporting Involvement...ChlamydiaChlamydiaHerpesviridae, Including CMV...Direct Infection of Cultured...Effects of Infection and...The Weight of the...On Transfer to a...Unanswered Questions and Areas...Summary and AssessmentReferences |
|---|
The ability of various infectious agents and their secreted products to alter vascular cell functions in a manner that might promote vascular disease constitutes one of the most intellectually tantalizing aspects of this subject (Fig 1
).
|
Effects on blood coagulation and fibrinolysis. Numerous studies have addressed changes in procoagulant and anticoagulant functions of endothelial cells infected by viruses.48–53 For example, herpes simplex virus infection of endothelial cells augments the surface expression of tissue factor, a potent procoagulant.54 This and other effects of herpesvirus do not require a productive infection. CMV infection likewise induces endothelial cell procoagulant activity.41,49,55 Infections with viruses can alter other aspects of the ability of endothelial cells to maintain blood in an unclotted state. These effects include inhibition of plasminogen activator, reduced levels of endothelial thrombomodulin, and loss of heparin sulfate proteoglycan, among other factors that regulate thrombosis.56 Little information exists regarding the effects of Chlamydia infection on the regulation of endothelial cell functions related to blood clotting. Like other Gram-negative bacteria, Chlamydia species release a lipopolysaccharide endotoxin. The ability of C pneumonia–derived lipopolysaccharide to activate endothelial functions that promote blood clotting, as in the case of Escherichia coli–derived endotoxin, remains unknown.
Ability of infectious agents to alter growth of vascular smooth muscle cells. The quest for Herpesviridae in human atheroma emerged from the concept that proliferation of a single virally transformed smooth muscle cell could account for the apparently monoclonal expansion of these cells in arteriosclerotic lesions.57,58 Indeed, herpesvirus can transform rabbit aortic smooth muscle cells. Such cell lines can become "immortalized," in the cell biologist's parlance, and thus escape usual growth control mechanisms.59
Recent evidence has suggested another specific manner in which CMV might influence arterial lesions. CMV infection can result in cytoplasmic sequestration of the tumor suppressor p53, perhaps because of complex formation with the viral immediate early gene product IE84.60 Infection with human CMV protects human endothelial cells from apoptosis resulting from serum lack.61 In this manner, CMV-infected vascular cells might evade a usual check on proliferation.
Few or no data in the literature support a role for bacterial infection, including C pneumoniae, in the modulation of vascular cell growth or transformation.
Effects of infectious agents on lipid metabolism. Infection of chickens with Marek's disease virus promotes cholesterol accumulation in the arterial wall. Herpes simplex virus infection decreases lysosomal hydrolysis of cholesterol esters by the acidic cholesteryl ester hydrolase in vascular smooth muscle cells.39,62,63 Herpesvirus infection also decreases the production of prostacyclin and other arachidonic acid metabolites. The consequent reduction in adenyl cyclase activity and cAMP concentration lowers the activity of protein kinase A, decreases the activity of the cytoplasmic cholesteryl ester hydrolase, and promotes accumulation of intracellular cholesteryl esters.63 Little evidence supports a role for infection by bacteria, including C pneumoniae, in the modulation of lipid metabolism in vascular cells.
Alteration of cytokine and other mediator
production by infectious agents. Vascular cells, including
smooth muscle, endothelium, and leukocytes, commonly
found in atherosclerotic lesions can produce as well as respond to
cytokines.64 These protein mediators of
inflammation and immunity can alter many vascular functions related to
atherosclerosis and restenosis. CMV infection
in vitro can augment macrophage production of messenger
RNAs encoding the cytokines interleukin-1ß, tumor necrosis
factor-
, and macrophage-colony–stimulating
factor.65 Likewise, infection of mononuclear cells by
Herpes simplex or Epstein-Barr virus augments cytokine
production.66 CMV can induce tumor necrosis
factor- expression in human monocytes.67 CMV infection
can also alter cytokine production by
endothelial cells.68
Bacterial lipopolysaccharides are classic activators of cytokine production from mononuclear phagocytes as well as intrinsic vascular wall cells. Ample evidence supports the role of bacterial endotoxins as regulators of production of such cytokines as interleukin-1 and tumor necrosis factor from human vascular endothelial and smooth muscle cells.69–71 Most of these studies have used endotoxins derived from various strains of E coli. The effects of lipopolysaccharides derived from Chlamydia species has not been tested in this regard. This is an important issue, because the potent effects of E coli–derived endotoxins on cellular activation cannot necessarily be extrapolated to lipopolysaccharides derived from other bacterial species.72
Induction of leukocyte adhesion molecules by infectious agents and their products. Interactions between leukocytes and the vascular endothelium participate in many forms of vascular disease, including aspects of atherogenesis. E coli endotoxin and cytokines typically released from endotoxin-stimulated cells augment the expression by endothelial cells of many of the adhesion molecules implicated in atherogenesis, including vascular cell adhesion molecule-1, intercellular adhesion molecule-1, and P-selectin. Similarly, infection of endothelial cells with CMV can induce the expression of endothelial-leukocyte adhesion molecules such as intercellular adhesion molecule-1.73 Endothelial cells infected with herpesvirus hominis express a monocyte receptor.74 By augmenting the expression of such leukocyte adhesion molecules, bacterial and viral infection could influence this crucial aspect of atherogenesis.
Systemic and Indirect Effects of Infectious Agents in Arterial
Diseases
In addition to the direct effects of infection and microbial
products on vascular functions, various systemic effects of
infection may influence atherogenesis and its manifestations (Fig 2).
|
Potential effects of infections on atherogenesis mediated by the acute-phase response. The host response to infectious agents usually involves a change in the program of hepatic protein synthesis. The cytokine interleukin 6 may mediate much of this switch from production of "housekeeping" proteins, such as albumin, to greater synthesis of proteins collectively known as "acute-phase reactants," some of which may influence atherogenesis. Augmented production of fibrinogen and plasminogen activator inhibitor during the acute-phase response could promote thrombosis. Increased production of serum amyloid A protein can alter the potential function of HDL in cholesterol export from atheromatous lesions and in coronary risk.75 Also, systemic infections can decrease HDL cholesterol concentrations.76
Systemic infection and triggering of acute coronary events. An ample literature links infectious processes and acute myocardial infarction.77 The foregoing section examined ways in which the acute-phase response to such infections might promote atherogenesis or thrombosis. This section will examine how other aspects of the pathophysiology of acute infection might trigger acute coronary events. Physical disruption of atherosclerotic plaques commonly precipitates the acute coronary syndromes.78 Plaque disruption in turn depends on a balance of the anatomic substrate (the so-called "vulnerable" plaque) and the biomechanical forces brought to bear on the atheroma. Acute infections might alter these biomechanical variables. For example, the tachycardia and increased cardiac output that accompany many acute infections and febrile illnesses could increase the wall stress experienced by an atheromatous plaque. This could trigger coronary events by promoting disruption of vulnerable plaques.
Systemic endotoxemia and atherogenesis and acute coronary events. Bacterial endotoxins profoundly influence local functions of vascular wall cells. During Gram-negative bacterial sepsis, circulating endotoxin provokes profound alterations in physiology. In addition to hypotension and decreased systemic vascular resistance, endotoxemia diffusely activates the endothelium, promoting the development of the disseminated intravascular coagulation that commonly accompanies Gram-negative sepsis.79,80 Reduced cardiac perfusion due to the hypotension associated with sepsis and/or an augmented susceptibility to clot formation due to endothelial activation could also precipitate acute coronary events.80
Even if episodes of endotoxemia or systemic infection do not provoke acute coronary events, they may influence local vascular functions related to atheroma formation and evolution. We hypothesized that local "echos" of systemic endotoxemia or cytokinemia may evoke a wave of heightened local cytokine production in the atheroma by resident cells and macrophages.81,82 Experimental support for this notion derives from studies in which systemic administration of endotoxin to rabbits with diet-induced atheroma yielded increased cytokine gene expression in the aorta in relation to the amount of preexisting atheroma.81 In this manner, episodes of infectious illness could lead to a crisis in the evolution of atheroma-enhancing lesion development.
Indeed, serial angiographic studies indicate that human
atheromas do not progress linearly in time.83
Rather, these lesions appear to undergo periodic spurts of growth, as
determined by luminal encroachment on angiograms. Many of these
transient episodes of plaque enlargement may result from disruption and
healing. In some cases, systemic infections might promote these
episodes of plaque disruption by inflammatory or infectious activation
of vascular wall cells or lesional leukocytes (Figs 1 and 2). In other
cases, the locally induced burst of cytokine production
due to infection might promote plaque growth even in the absence of
physical disruption.
|
The Weight of the Evidence: Are Koch's Postulates Fulfilled? |
|---|
|
TopIntroductionEvidence Supporting Involvement...ChlamydiaChlamydiaHerpesviridae, Including CMV...Direct Infection of Cultured...Effects of Infection and...The Weight of the...On Transfer to a...Unanswered Questions and Areas...Summary and AssessmentReferences |
|---|
More than a century ago, Robert Koch proposed three criteria that should be met to link an infectious agent causally with production of a disease. Koch used these postulates to implicate the tubercle bacillus as the culpable microbe in tuberculosis. Does the present state of knowledge of infectious agents in relation to atherosclerosis and restenosis fulfill these criteria? Let us consider Koch's original postulates in turn.
The Causative Organism Can Be Isolated From the Affected
Host
Attempts to culture infectious viruses from atheroma
have generally failed. Likewise, the propagation of C
pneumoniae from human atherosclerotic lesions is anecdotal. The
presence of antigens associated with these infectious agents and/or
nucleic acid characteristic of these agents is not an explicit
criterion of Koch's postulates. Although human atheromas
often contain such evidence of the presence of infectious agents, many
cases lack these indirect indications of the presence of the agents.
Moreover, even if infectious particles are present within the
lesions, a pathogenic role is far from established.
The Infectious Agent Can Be Identified by Culture or Directly
by Microscopy
In the case of CMV and Chlamydia, the agents are
extremely well characterized with a good deal of information about
their biology. This criterion is met not only in vitro but often in
situ within lesions, as noted above.
|
On Transfer to a Susceptible Host, the Infectious Agent Must Produce the Disease |
|---|
|
TopIntroductionEvidence Supporting Involvement...ChlamydiaChlamydiaHerpesviridae, Including CMV...Direct Infection of Cultured...Effects of Infection and...The Weight of the...On Transfer to a...Unanswered Questions and Areas...Summary and AssessmentReferences |
|---|
In the case of Marek's disease in chickens, this criterion has been approached. At present, however, Koch's postulates in regard to an infectious cause of atherosclerosis or restenosis remain unfulfilled in humans.
It could be argued that Koch's postulates are irrelevant to a chronic disease that usually develops over decades. For example, previous infection with CMV or another virus could alter the function of cells permanently without persistence of the agents. Such a hit-and-run mechanism seems to apply to certain experimental tumors associated with herpesvirus infection. In contrast with the clarity of the epidemiological links between traditional risk factors for coronary heart disease (eg, hypercholesterolemia and hypertension), however, the evidence regarding involvement of Chlamydia and Herpesviridae in atherosclerosis remains rudimentary at present.
A possible instance in which an infectious agent could cause a disease without meeting Koch's postulates would be if it induced an immune response by antigenic mimicry. Another complexity not envisaged by Koch would be the dependence of the histocompatibility haplotype of an individual for susceptibility to infection. Particularly with viral agents, it is conceivable that only a subgroup of the population at large that had certain HLA haplotypes would be susceptible to the viral infection. This could explain lack of disease in some individuals exposed to the putative pathogen. Conversely, an equally vigorous argument to the contrary could be made. One could hold that herpesviruses, including CMV, are virtually ubiquitous. Their presence in atherosclerotic lesions may have no relationship whatsoever to disease production. Likewise, one could conceive that Chlamydia localizes more commonly in atherosclerotic lesions than in uninvolved arteries merely because of the presence of macrophages, which could harbor an innocent persistence of this common microbial pathogen.
Indeed, some combination of these contrasting situations could pertain to human atherosclerosis. In some cases, a viral arteritis could furnish the substrate for an atheroma, decisively setting the stage for its subsequent development, perhaps in combination with traditional risk factors such as hypercholesterolemia. The potentiating effect of an atherogenic diet from the development of arterial disease in chickens infected with the Marek's disease virus provides an example of such a mechanism. In the case of Chlamydia, persistent infection of lesional macrophages might potentiate atherogenesis by heightening cytokine and growth factor release from the phagocytic cells within the atheroma. Thus, the Chlamydia infection, although not a primary pathogenic stimulus, could hasten development of atheroma.
Although we must conclude that no infectious agent meets Koch's original postulates at present, we need not therefore discard the notion that infectious agents play a pivotal role in atherogenesis in some situations in which infections, when present, may promote the atherogenic process.84 Indeed, H pylori does not meet Koch's postulates as a causative organism for duodenal ulcer.85 Various workers have argued persuasively that Koch's postulates may lack sufficient sensitivity to reject a causal link between an infectious agent and a given disease.86
|
Unanswered Questions and Areas for Future Research |
|---|
|
TopIntroductionEvidence Supporting Involvement...ChlamydiaChlamydiaHerpesviridae, Including CMV...Direct Infection of Cultured...Effects of Infection and...The Weight of the...On Transfer to a...Unanswered Questions and Areas...Summary and AssessmentReferences |
|---|
Laboratory Investigations of the Vascular Biology of Infectious
Agents in Relation to Atherogenesis and Restenosis
A great deal of in vitro work has probed potential mechanisms
whereby Herpesviridae, including herpesvirus hominis and CMV, can alter
the functions of vascular wall cells in ways that may promote
atherosclerosis or restenosis. Yet a number of
fundamental issues remain relatively unexplored. It is unknown how
herpesviruses enter the arterial wall. A potential
mechanism could involve entry into the artery wall, with blood
monocytes known to accumulate in these lesions. Under ordinary
circumstances, monocytes are minimally permissive for herpesvirus
infection. However, differentiation of mononuclear phagocytes toward
the macrophage phenotype by such agents as vitamin
D3 can augment virus yield from infected cells. The general
inability to culture herpesvirus from atheromatous
lesions may result from limited permissivity of vascular cells for
virus replication. However, in some otherwise nonpermissive cell types,
exposure to growth factors, such as fibroblast growth factor, can
enhance viral gene expression. Smooth muscle cells in atherosclerotic
lesions and in injured arteries may encounter fibroblast growth
factors. The interactions between growth factors and smooth muscle
cells might thus influence their interaction with herpesviruses in ways
that might be important to the evolution of vascular lesions. Systemic
factors might also influence the activity of latent herpesviruses in
atherosclerotic lesions. For example, glucocorticoids, hormones
released during stress, can enhance transcription of herpesvirus latent
in cells.87 Thus, a quiescent herpesvirus infection might
be reactivated by such a mechanism, much as glucocorticoids or
stress can reactivate latent Herpes zoster.
Although the interaction of herpesviruses, including CMV, in the artery wall has received much attention in the past, study of the vascular effects of Chlamydia has barely begun. Just as in the case of viruses, it is important to know how Chlamydia enter the artery wall. Could these agents enter in mononuclear phagocytes? Does the degree of differentiation of the mononuclear phagocyte or the stimuli that it may encounter in the vessel wall influence the latency of productivity of the infection? Specifically, would gamma interferon, a cytokine found within atheroma, favor a persistent infection of macrophages as in the case of certain transformed cell lines? What effects do the lipopolysaccharides produced by Chlamydia have on vessel wall cells and macrophages? Could major chlamydial proteins, such as the major outer membrane protein or heat shock protein, serve as antigens for a cellular or humoral immune response and thus add to the chronic immune response ongoing in atherosclerotic lesions?
Need for In Vivo Animal Models to Study the Interaction Between
Infectious Agents and Atherosclerosis
As described above, the scientific foundation of the relationship
between infection and atherosclerosis rests on the
convincing data emerging from the avian herpesvirus infection, Marek's
disease in chickens. Short of satisfying Koch's postulates in humans,
the notion that infectious agents can provoke or potentiate
arterial disease could benefit enormously from development
of further animal models, particularly in mammalian species.
The advent of genetically modified mice susceptible to atherosclerosis, such as those lacking apolipoprotein E or the low-density lipoprotein receptor, has ushered in a new era of animal investigation of atherosclerosis. These new animal models provide lesions that share many more features of human atherosclerosis than previously achievable in rodents. Although differences in species permissivity require consideration, attempts to study the interaction of infectious agents with atheroma formation in these novel animal preparations seems worthy. The ability to infect apolipoprotein E–deficient mice with C pneumoniae provides support for this particular avenue toward development of relevant animal models.38 Doubtless, other species would be appropriate for testing various hypotheses regarding the interaction of infectious agents and atherosclerosis and restenosis, including rabbits, swine, and nonhuman primates.
Clinical Studies Regarding Infectious Causes of
Atherosclerosis and Restenosis
A large database of seroepidemiological studies, reviewed above,
has established grounds for a clinically relevant link between
Chlamydia and CMV with atherosclerosis and,
in the case of CMV, with restenosis after angioplasty. In the
realm of seroepidemiological studies, increasing the number of surveys
of relatively small numbers of patients at a single center is not
likely to provide further illumination. Retrospective studies are
subject to well-known biases. Moreover, it is difficult to compare
results across various seroepidemiological studies because of
differences in reagents and assay protocols and in patient selection. A
standardized set of reagents, protocols, and perhaps a core testing
laboratory would facilitate future seroepidemiological studies. In
particular, studies of geographically diverse populations with
differing risks for atherosclerosis could provide new
insight in testing of the relationship between infectious diseases and
atherosclerosis. Ultimately, a well-designed and
sufficiently powered prospective cohort study relating evidence for
infection to future risk of cardiovascular disease and
controlling for confounding variables (eg, smoking) would help to
strengthen the seroepidemiological evidence for a causal role of
infectious agents in aggravating atherosclerotic disease. Use of stored
samples from previous clinical studies provides another potential
source of materials for further study in this context.
Some have proposed consideration of a clinical trial of antibiotic therapy after coronary events as end points. Such studies would test the hypothesis that bacterial agents such as Chlamydia, for which effective antibiotic therapies exist, contribute to coronary events. A number of outstanding issues require resolution before we embark on such therapeutic trials. Criteria for defining a subset of patients with evidence of Chlamydia infection would prove helpful in targeting individuals who enter into a secondary prevention trial. Questions regarding the dose, duration, and choice of antibiotic agent would require considerable deliberation. Likewise, vaccination might provide a way to limit infection with microbial or viral agents implicated in atherogenesis.
However, a therapeutic trial of antibiotics still would not establish a causal relationship between any particular infectious agent, eg, Chlamydia, and atherosclerosis. Nonspecific effects of the antibiotic agent used in such a trial might influence the outcome. For example, tetracyclines can inhibit metalloproteinases, which may contribute to acute coronary syndromes. Other unexpected or unknown effects of antibiotics might confound conclusions regarding causality even in a successful therapeutic trial. Moreover, most antibiotics target a number of microorganisms, rendering conclusions about the causal contribution of any one susceptible organism difficult. Yet, if antibiotic treatment or vaccination could reduce atherosclerotic events, the public health implications could be enormous; hence the need to keep an open mind and seek further information through continued research focused on the relationship between infectious agents and vascular diseases. Certainly, increased understanding of the basic vascular biology of infection in relation to arterial diseases and creation of relevant animal models would facilitate resolution of these issues.
|
Summary and Assessment |
|---|
|
TopIntroductionEvidence Supporting Involvement...ChlamydiaChlamydiaHerpesviridae, Including CMV...Direct Infection of Cultured...Effects of Infection and...The Weight of the...On Transfer to a...Unanswered Questions and Areas...Summary and AssessmentReferences |
|---|
Observational studies in humans provide intriguing hints relating infectious agents such as certain viruses and bacteria to atherosclerosis, coronary events, or restenosis after arterial intervention. A number of recent seroepidemiological and pathological studies support an association between C pneumoniae and coronary atherosclerosis. Also, emerging data have rekindled interest in the role of CMV in arterial diseases such as restenosis. A large body of in vitro work provides a pathophysiological foundation for a contribution of Herpesviridae, including CMV, in vascular pathology. Information regarding C pneumoniae at the basic science level remains scant. The Marek's disease in chickens model provides strong experimental support for in vivo potentiation of cholesterol-induced fibrofatty lesion formation in arteries. Similar data regarding the relationship between bacterial infection and atherosclerosis have not yet emerged.
The pressing question that remains unanswered is whether infections are a cause, a cofactor, or a commensal of no pathological import in the context of atheroma.88 Only further basic science and clinical research can shed light on this issue and promote a better understanding of the roles of infection in arterial disease. Perhaps such efforts will aid in the identification of a population appropriate for particular surveillance or a specific intervention such as antibiotic therapy.
Note added in proof
Since acceptance of this manuscript, Danesh et al published a
related review,89 and two intriguing preliminary studies
showing reduction in recurrent coronary events in patients treated with
macrolide antibiotics have appeared.90,91
|
Acknowledgments |
|---|
The authors acknowledge the members of the special emphasis panel, who each contributed to the concepts explored in this paper, including Drs James T. Grayston, James Melnick, David P. Hajjar, Steven E. Epstein, Hannah Valantine, George Byrne, Priscilla Schaffer, Gregory Vercellotti, Maurice Nachtigal, Lewis H. Kuller, Gail H. Cassell, and David S. Siskovick. We thank Drs Amir Kol and Paul Ridker for critical reading of the manuscript.
|
Footnotes |
|---|
1 The authors convened a special emphasis panel on September 19, 1996, under the auspices of the National Heart, Lung, and Blood Institute to examine the role of infectious agents in atherosclerosis and restenosis. The members of the panel included James T. Grayston, James Melnick, David P. Hajjar, Steven E. Epstein, Hannah Valantine, George Byrne, Priscilla Schaffer, Gregory Vercellotti, Maurice Nachtigal, Peter Libby, and Lewis H. Kuller. Invited discussants included Dr Gail H. Cassell and Dr David S. Siskovick. The information and views expressed in this article are based on the deliberations of the panel, edited and commented on by the authors. The views expressed in this document do not constitute an official position of the panelists, the National Heart, Lung, and Blood Institute, the National Institutes of Health, or the US Government.
|
References |
|---|
|
TopIntroductionEvidence Supporting Involvement...ChlamydiaChlamydiaHerpesviridae, Including CMV...Direct Infection of Cultured...Effects of Infection and...The Weight of the...On Transfer to a...Unanswered Questions and Areas...Summary and AssessmentReferences |
|---|
1. Melnick JL, Adam E, DeBakey ME. Possible role of cytomegalovirus in atherogenesis. JAMA. 1990;263:2204–2207.
2. Melnick JL, Adam E, Debakey ME. Cytomegalovirus and atherosclerosis. Eur Heart J. 1993;14:30–38.
3.
Heiss G, Sharrett AR, Barnes R, Chambless LE, Szklo M,
Alzola C. Carotid atherosclerosis measured by B-mode
ultrasound in populations: associations with
cardiovascular risk factors in the ARIC study.
Am J Epidemiol. 1991;134:250–256.
4.
Nieto FJ, Adam E, Sorlie P, Farzadegan H,
Melnick JL, Comstock GW, Szklo M. Cohort study of cytomegalovirus
infection as a risk factor for carotid intimal-medial thickening, a
measure of subclinical atherosclerosis.
Circulation. 1996;94:922–927. See comments.
5.
Zhou YF, Leon MB, Waclawiw MA, Popma JJ, Yu ZX, Finkel
T, Epstein SE. Association between prior cytomegalovirus infection and
the risk of restenosis after coronary atherectomy.
N Engl J Med. 1996;335:624–630.
6.
Grattan MT, Moreno-Cabral CE, Starnes VA, Oyer PE,
Stinson EB, Shumway NE. Cytomegalovirus infection is associated with
cardiac allograft rejection and atherosclerosis.
JAMA. 1989;261:3561–3566.
7. Pahl E, Fricker FJ, Armitage J, Griffith BP, Taylor S, Uretsky BF, Beerman LB, Zuberbuhler JR. Coronary arteriosclerosis in pediatric heart transplant survivors: limitation of long-term survival. J Pediatr. 1990;116:177–183.[Medline] [Order article via Infotrieve]
8. Loebe M, Schuler S, Zais O, Warnecke H, Fleck E, Hetzer R. Role of cytomegalovirus infection in the development of coronary artery disease in the transplanted heart. J Heart Transplant. 1990;9:707–711.[Medline] [Order article via Infotrieve]
9. Everett JP, Hershberger RE, Norman DJ, Chou S, Ratkovec RM, Cobanoglu A, Ott GY, Hosenpud JD. Prolonged cytomegalovirus infection with viremia is associated with development of cardiac allograft vasculopathy. J Heart Lung Transplant. 1992;11:S133–S137.[Medline] [Order article via Infotrieve]
10. Dummer S, Lee A, Breinig MK, Kormos R, Ho M, Griffith B. Investigation of cytomegalovirus infection as a risk factor for coronary atherosclerosis in the explanted hearts of patients undergoing heart transplantation. J Med Virol. 1994;44:305–309.[Medline] [Order article via Infotrieve]
11. Saikku P, Leinonen M, Mattila K, Ekman MR, Nieminen MS, Makela PH, Huttunen JK, Valtonen V. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet. 1988;2:983–986.[Medline] [Order article via Infotrieve]
12. Saikku P, Leinonen M, Tenkanen L, Linnanmaki E, Ekman MR, Manninen V, Manttari M, Frick MH, Huttunen JK. Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. Ann Intern Med. 1992;116:273–278. See comments.
13.
Thom DH, Wang SP, Grayston JT, Siscovick DS, Stewart
DK, Kronmal RA, Weiss NS. Chlamydia pneumoniae strain TWAR antibody and
angiographically demonstrated coronary artery disease.
Arterioscler Thromb. 1991;11:547–551.
14.
Thom DH, Grayston JT, Siscovick DS, Wang SP, Weiss NS,
Daling JR. Association of prior infection with Chlamydia pneumoniae and
angiographically demonstrated coronary artery disease.
JAMA. 1992;268:68–72.
15.
Hahn DL, Golubjatnikov R. Smoking is a potential
confounder of the Chlamydia pneumoniae-coronary artery disease
association. Arterioscler Thromb. 1992;12:945–947.
16. Galloway DA, McDougall JK. The oncogenic potential of herpes simplex viruses: evidence for a `hit-and-run' mechanism. Nature. 1983;302:21–24.[Medline] [Order article via Infotrieve]
17.
Benditt EP, Barrett T, McDougall JK. Viruses in the
etiology of atherosclerosis. Proc Natl Acad Sci
U S A. 1983;80:6386–6389.
18. Hendrix MG, Salimans MM, van Boven CP, Bruggeman CA. High prevalence of latently present cytomegalovirus in arterial walls of patients suffering from grade III atherosclerosis. Am J Pathol. 1990;136:23–28.[Abstract]
19. Wu TC, Hruban RH, Ambinder RF, Pizzorno M, Cameron DE, Baumgartner WA, Reitz BA, Hayward GS, Hutchins GM. Demonstration of cytomegalovirus nucleic acids in the coronary arteries of transplanted hearts. Am J Pathol. 1992;140:739–747.[Abstract]
20.
Kol A, Sperti G, Shani J, Schulhoff N, van de
Greef W, Landini MP, La Placa M, Maseri A, Crea F. Cytomegalovirus
replication is not a cause of instability in unstable angina.
Circulation. 1995;91:1910–1913.
21. Hendrix MG, Dormans PH, Kitslaar P, Bosman F, Bruggeman CA. The presence of cytomegalovirus nucleic acids in arterial walls of atherosclerotic and nonatherosclerotic patients. Am J Pathol. 1989;134:1151–1157.[Abstract]
22. Hendrix MG, Daemen M, Bruggeman CA. Cytomegalovirus nucleic acid distribution within the human vascular tree. Am J Pathol. 1991;138:563–567.[Abstract]
23. Grayston JT, Kuo CC, Campbell LA, Benditt EP. Chlamydia pneumoniae, strain TWAR and atherosclerosis. Eur Heart J. 1993;14:66–71.
24. Jackson LA, Campbell LA, Schmidt RA, Kuo C-C, Cappuccio AL, Lee MJ, Grayston JT. Specificity of detection of Chlamydia pneumoniae in cardiovascular atheroma: evaluation of the innocent bystander hypothesis. Am J Pathol. 1997;150:1785–1790.[Abstract]
25. Kuo CC, Shor A, Campbell LA, Fukushi H, Patton DL, Grayston JT. Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries. J Infect Dis. 1993;167:841–849.[Medline] [Order article via Infotrieve]
26. Kuo CC, Gown AM, Benditt EP, Grayston JT. Detection of Chlamydia pneumoniae in aortic lesions of atherosclerosis by immunocytochemical stain. Arterioscler Thromb. 1993;13: 1501–1504.
27.
Kuo CC, Grayston JT, Campbell LA, Goo YA, Wissler RW,
Benditt EP. Chlamydia pneumoniae (TWAR) in coronary arteries of
young adults (15–34 years old). Proc Natal Acad Sci
U S A. 1995;92:6911–6914.
28.
Grayston JT, Kuo CC, Coulson AS, Campbell LA, Lawrence
RD, Lee MJ, Strandness ED, Wang SP. Chlamydia pneumoniae (TWAR) in
atherosclerosis of the carotid artery.
Circulation. 1995;92:3397–3400. See comments.
29. Muhlestein JB, Hammond EH, Carlquist JF, Radicke E, Thomson MJ, Karagounis LA, Woods ML, Anderson JL. Increased incidence of Chlamydia species within the coronary arteries of patients with symptomatic atherosclerotic versus other forms of cardiovascular disease. J Am Coll Cardiol. 1996;27:1555–1561.[Abstract]
30. Weiss SM, Roblin PM, Gaydos CA, Cummings P, Patton DL, Schulhoff N, Shani J, Frankel R, Penney K, Quinn TC, Hammerschlag MR, Schachter J. Failure to detect Chlamydia pneumoniae in coronary atheromas of patients undergoing atherectomy. J Infect Dis. 1996;173:957–962.[Medline] [Order article via Infotrieve]
31.
Cook PJ, Lip GY. Infectious agents and atherosclerotic
vascular disease. Q J Med. 1996;89:727–735.
32. Minick CR, Fabricant CG, Fabricant J, Litrenta MM. Atheroarteriosclerosis induced by infection with a herpesvirus. Am J Pathol. 1979;96:673–706.[Abstract]
33. Pyrzak R, Shih JC. Detection of specific DNA segments of Marek's disease herpes virus in Japanese quail susceptible to atherosclerosis. Atherosclerosis. 1987;68:77–85.[Medline] [Order article via Infotrieve]
34. Shih JC, Pyrzak R, Guy JS. Discovery of noninfectious viral genes complementary to Marek's disease herpes virus in quail susceptible to cholesterol-induced atherosclerosis. J Nutr. 1989;119:294–298.
35.
Lemstrom K, Koskinen P, Krogerus L, Daemen M, Bruggeman
C, Hayry P. Cytomegalovirus antigen expression,
endothelial cell proliferation, and intimal thickening
in rat cardiac allografts after cytomegalovirus infection.
Circulation. 1995;92:2594–2604.
36. Koskinen P, Lemstrom K, Bruggeman C, Lautenschlager I, Hayry P. Acute cytomegalovirus infection induces a subendothelial inflammation (endothelialitis) in the allograft vascular wall: a possible linkage with enhanced allograft arteriosclerosis. Am J Pathol. 1994;144:41–50.[Abstract]
37. Moazed TC, Kuo C, Patton DL, Grayston JT, Campbell LA. Experimental rabbit models of Chlamydia pneumoniae infection. Am J Pathol. 1996;148:667–676.[Abstract]
38. Moazed TC, Kuo C, Grayston JT, Campbell LA. Murine models of Chlamydia pneumoniae infection and atherosclerosis. J Infect Dis. 1997;175:883–890.[Medline] [Order article via Infotrieve]
39. Hajjar DP, Pomerantz KB, Falcone DJ, Weksler BB, Grant AJ. Herpes simplex virus infection in human arterial cells: implications in arteriosclerosis. J Clin Invest. 1987;80:1317–1321.
40.
Ho DD, Rota TR, Hirsch MS. Infection of human
endothelial cells by human T-lymphotropic virus type I.
Proc Natl Acad Sci U S A. 1984;81:7588–7590.
41. Van Dam-Mieras MC, Bruggeman CA, Muller AD, Debie WH, Zwaal RF. Induction of endothelial cell procoagulant activity by cytomegalovirus infection. Thromb Res. 1987;47:69–75.[Medline] [Order article via Infotrieve]
42. Span AH, Frederik PM, Grauls G, Van Boven GP, Bruggeman CA. CMV induced vascular injury: an electron-microscopic study in the rat. In Vivo. 1993;7:567–573.[Medline] [Order article via Infotrieve]
43. Steinhoff G, You XM, Steinmuller C, Boeke K, Stals FS, Bruggeman CA, Haverich A. Induction of endothelial adhesion molecules by rat cytomegalovirus in allogeneic lung transplantation in the rat. Scand J Infect Dis. 1995;99(suppl):58–60.
44. Gaydos CA, Summersgill JT, Sahney NN, Ramirez JA, Quinn TC. Replication of Chlamydia pneumoniae in vitro in human macrophages, endothelial cells, and aortic artery smooth muscle cells. Infect Immun. 1996;64:1614–1620.[Abstract]
45.
Beatty WL, Byrne GI, Morrison RP. Morphologic and
antigenic characterization of interferon gamma-mediated persistent
Chlamydia trachomatis infection in vitro. Proc Natl Acad
U S A.. 1993;90:3998–4002.
46. Beatty WL, Byrne GI, Morrison RP. Repeated and persistent infection with Chlamydia and the development of chronic inflammation and disease. Trends Microbiol. 1994;2:94–98. See comments.[Medline] [Order article via Infotrieve]
47.
Beatty WL, Morrison RP, Byrne GI. Persistent
chlamydiae: from cell culture to a paradigm for chlamydial
pathogenesis. Microbiol Rev. 1994;58:686–699.
48.
Visser MR, Tracy PB, Vercellotti GM, Goodman JL, White
JG, Jacob HS. Enhanced thrombin generation and platelet binding on
herpes simplex virus-infected endothelium. Proc
Natl Acad U S A. 1988;85:8227–8230.
49. Etingin OR, Silverstein RL, Friedman HM, Hajjar DP. Viral activation of the coagulation cascade: molecular interactions at the surface of infected endothelial cells. Cell. 1990;61:657–662.[Medline] [Order article via Infotrieve]
50. Bok RA, Jacob HS, Balla J, Juckett M, Stella T, Shatos MA, Vercellotti GM. Herpes simplex virus decreases endothelial cell plasminogen activator inhibitor. Thromb Haemost. 1993;69:253–258.[Medline] [Order article via Infotrieve]
51. Visser MR, Vercellotti GM. Herpes simplex virus and atherosclerosis. Eur Heart J. 1993;14:39–42.
52.
Kaner RJ, Baird A, Mansukhani A, Basilico C, Summers
BD, Florkiewicz RZ, Hajjar DP. Fibroblast growth factor receptor is a
portal of cellular entry for herpes simplex virus type 1.
Science. 1990;248:1410–1413. See comments.
53.
Key NS, Vercellotti GM, Winkelmann JC, Moldow CF,
Goodman JL, Esmon NL, Esmon CT, Jacob HS. Infection of vascular
endothelial cells with herpes simplex virus enhances
tissue factor activity and reduces thrombomodulin expression.
Proc Natl Acad U S A. 1990;87:7095–7099.
54. Key NS, Bach RR, Vercellotti GM, Moldow CF. Herpes simplex virus type I does not require productive infection to induce tissue factor in human umbilical vein endothelial cells. Lab Invest. 1993;68:645–651.[Medline] [Order article via Infotrieve]
55. van Dam-Mieras MC, Muller AD, van Hinsbergh VW, Mullers WJ, Bomans PH, Bruggeman CA. The procoagulant response of cytomegalovirus infected endothelial cells. Thromb Haemost. 1992;68:364–370.[Medline] [Order article via Infotrieve]
56. Vercellotti GM. Proinflammatory and procoagulant effects of herpes simplex infection on human endothelium. Blood Cells. 1990;16:209–215.[Medline] [Order article via Infotrieve]
57.
Benditt EP, Benditt JM. Evidence for a monoclonal
origin of human atherosclerotic plaques. Proc Natl Acad
U S A. 1973;70:1753–1756.
58. Benditt EP. Implications of the monoclonal character of human atherosclerotic plaques. Am J Pathol. 1977;86:693–702.[Abstract]
59. Nachtigal M, Legrand A, Greenspan P, Nachtigal SA, Nagpal ML. Immortalization of rabbit vascular smooth muscle cells after transfection with a fragment of the BglII N region of herpes simplex virus type 2 DNA. Intervirology. 1990;31:166–174.[Medline] [Order article via Infotrieve]
60.
Speir E, Modali R, Huang ES, Leon MB, Shawl F, Finkel
T, Epstein SE. Potential role of human cytomegalovirus and p53
interaction in coronary restenosis. Science. 1994;265:391–394.
61. Kovacs A, Weber M, Burns L, Jacob H, Vercellotti G. Cytoplasmic sequestration of p53 in cytomegalovirus-infected human endothelial cells. Am J Pathol. 1996;149:1531–1539.[Abstract]
62. Hajjar DP, Fabricant CG, Minick CR, Fabricant J. Virus-induced atherosclerosis. Herpesvirus infection alters aortic cholesterol metabolism and accumulation. Am J Pathol. 1986;122:62–70.[Abstract]
63. Hajjar DP. Warner-Lambert/Parke-Davis Award Lecture. Viral pathogenesis of atherosclerosis: impact of molecular mimicry and viral genes. Am J Pathol. 1991;139:1195–1211.[Abstract]
64. Libby P. Vascular Cells Produce and Respond to Cytokines. In: Hansson GK, Libby P, eds. Immune Functions of the Vessel Wall. Amsterdam, Netherlands: Harwood Academic Publishers; 1996:45-64.
65. Dudding L, Haskill S, Clark BD, Auron PE, Sporn S, Huang ES. Cytomegalovirus infection stimulates expression of monocyte-associated mediator genes. J Immunol. 1989;143:3343–3352.[Abstract]
66. Gosselin J, Flamand L, D'Addario M, Hiscott J, Menezes J. Infection of peripheral blood mononuclear cells by herpes simplex and Epstein-Barr viruses: differential induction of interleukin 6 and tumor necrosis factor-alpha. J Clin Invest. 1992;89:1849–1856.
67. Smith PD, Saini SS, Raffeld M, Manischewitz JF, Wahl SM. Cytomegalovirus induction of tumor necrosis factor-alpha by human monocytes and mucosal macrophages. J Clin Invest. 1992;90:1642–1648.
68.
Almeida GD, Porada CD, St Jeor S, Ascensao JL. Human
cytomegalovirus alters interleukin-6 production by
endothelial cells. Blood. 1994;83:370–376.
69. Libby P, Ordovàs JM, Auger KR, Robbins H, Birinyi LK, Dinarello CA. Endotoxin and tumor necrosis factor induce interleukin-1 gene expression in adult human vascular endothelial cells. Am J Pathol. 1986;124:179–186.[Abstract]
70. Libby P, Ordovas JM, Birinyi LK, Auger KR, Dinarello CA. Inducible interleukin-1 expression in human vascular smooth muscle cells. J Clin Invest.1986;78:1432–1438.
71. Warner SJC, Libby P. Human vascular smooth muscle cells: target for and source of tumor necrosis factor. J Immunol. 1989;142:100–109.[Abstract]
72.
Loppnow H, Libby P, Freudenberg M, Krauss JH, Weckesser
J, Mayer H. Cytokine induction by lipopolysaccharide
(LPS) corresponds to lethal toxicity and is inhibited by nontoxic
Rhodobacter capsulatus LPS. Infect Immun. 1990;58:3743–3750.
73. Sedmak DD, Knight DA, Vook NC, Waldman JW. Divergent patterns of ELAM-1, ICAM-1, and VCAM-1 expression on cytomegalovirus-infected endothelial cells. Transplantation. 1994;58:1379–1385.[Medline] [Order article via Infotrieve]
74.
Etingin OR, Silverstein RL, Hajjar DP. Identification
of a monocyte receptor on herpesvirus-infected
endothelial cells. Proc Natl Acad U S A. 1991;88:7200–7203.
75. Van Lenten B, Hama SY, de Beer F, Stafforini DM, McIntyre TM, Prescott SM, La Du B, Fogelman AM, Navab M. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response: loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest. 1995;96:2758–2767.
76. Pesonen E, Rapola J, Viikari J, Turtinen J, Akerblom HK. Altered serum lipid profile after systemic infection in children: risk factor for CHD? Eur Heart J. 1993;14:7–11.
77. Nieminen MS, Mattila K, Valtonen V. Infection and inflammation as risk factors for myocardial infarction. Eur Heart J. 1993;14:12–16.
78.
Davies MJ, Thomas AC. Plaque fissuring: the cause
of acute myocardial infarction, sudden ischemic death, and
crescendo angina. Br Heart J. 1985;53:363–373.
79. Libby P, Loppnow H, Girard J. The Roles of Endothelial Cells in Septic Shock. In: Beaufils F, Mercier JC, eds. Chocs septiques en Pédiatrie. Paris, France: Arnette; 1989:25-32.
80. Parrillo JE, Parker MM, Natanson C, Suffredini AF, Danner RL, Cunnion RE, Ognibene FP. Septic shock in humans: advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. Ann Intern Med. 1990;113:227–242.
81. Fleet JC, Clinton SK, Salomon RN, Loppnow H, Libby P. Atherogenic diets enhance endotoxin-stimulated interleukin-1 and tumor necrosis factor gene expression in rabbit aortae. J Nutr. 1992;122:294–305.
82. Libby P. Do vascular wall cytokines promote atherogenesis? Hosp Pract. 1992;27:51–58.
83. Bruschke AV, Kramer J Jr, Bal ET, Haque IU, Detrano RC, Goormastic M. The dynamics of progression of coronary atherosclerosis studied in 168 medically treated patients who underwent coronary arteriography three times. Am Heart J. 1989;117:296–305. See comments.[Medline] [Order article via Infotrieve]
84.
Buja LM. Does atherosclerosis have an
infectious etiology? Circulation. 1996;94:872–873.
85. Marshall BJ. Helicobacter pylori in peptic ulcer: have Koch's postulates been fulfilled? Ann Med. 1995;27:565–568.[Medline] [Order article via Infotrieve]
86. Fredericks DN, Relman DA. Sequence-based identification of microbial pathogens: a reconsideration of Koch's postulates. Clin Microbiol Rev. 1996;9:18–33.[Abstract]
87. Hardwicke MA, Schaffer PA. Differential effects of nerve growth factor and dexamethasone on herpes simplex virus type 1 oriL- and oriS-dependent DNA replication in PC12 cells. Journal of Virology. 1997;71:3580–3587.[Abstract]
88. Capron L. Chlamydia in coronary plaques: hidden culprit or harmless hobo? Nat Med. 1996;2:856–857[Medline] [Order article via Infotrieve]
89. Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: is there a link? Lancet. 1997;350:430–436.[Medline] [Order article via Infotrieve]
90.
Gupta S, Leatham EW, Carrington D, Mendall MA, Kaski
JC, Camm AJ. Elevated Chlamydia pneumoniae antibodies,
cardiovascular events, and azithromycin in male survivors of myocardial
infarction. Circulation. 1997;96:404–407.
91. Gurfinkel E, Bozovich G, Daroca A, Beck E, Mautner B, for the ROXIS Study Group. Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS pilot study. Lancet. 1997;350:404–407.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
 |
|
 |
|
  M. Nachtigal, A. Ghaffar, and E. P. Mayer Galectin-3 Gene Inactivation Reduces Atherosclerotic Lesions and Adventitial Inflammation in ApoE-Deficient Mice Am. J. Pathol., January 1, 2008; 172(1): 247 - 255. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Demircan, A. T. Sezgin, M. Baltali, O. Gulcan, S. Topcu, F. Yigit, T. Erol, R. Turkoz, H. Muderrisoglu, and B. Ozin Intima-Media Thickness in Patients With Rheumatic Mitral Stenosis Angiology, November 1, 2007; 58(5): 614 - 619. [Abstract] [PDF]
|
|
|
|
 |
|
 G. A. Mensah, A. O. Grant, and C. J. Pepine ACCF/AHA/CDC Conference Report on Emerging Infectious Diseases and Biological Terrorism Threats: The Clinical and Public Health Implications for the Prevention and Control of Cardiovascular Diseases J. Am. Coll. Cardiol., March 27, 2007; 49(12): 1376 - 1379. [Full Text] [PDF]
|
|
|
|
|
|
M. Madjid, R. V. Luepker, K. J. Greenlund, K. A. Taubert, M. J. Roy, and R. M. Robertson Task Force IV: Cardiovascular Effects of Emerging Infectious Diseases and Biological Terrorism Threats: Basic, Clinical, and Population Science Research and Training Needs J. Am. Coll. Cardiol., March 27, 2007; 49(12): 1407 - 1412. [Full Text] [PDF]
|
|
|
|
 |
|
 X. Yang, V. Murthy, K. Schultz, J. B. Tatro, K. A. Fitzgerald, and D. Beasley Toll-like receptor 3 signaling evokes a proinflammatory and proliferative phenotype in human vascular smooth muscle cells Am J Physiol Heart Circ Physiol, November 1, 2006; 291(5): H2334 - H2343. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Tedgui and Z. Mallat Cytokines in Atherosclerosis: Pathogenic and Regulatory Pathways Physiol Rev, April 1, 2006; 86(2): 515 - 581. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. H. James, M. G. Jamison, M. S. Biswas, L. R. Brancazio, G. K. Swamy, and E. R. Myers Acute Myocardial Infarction in Pregnancy: A United States Population-Based Study Circulation, March 28, 2006; 113(12): 1564 - 1571. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. H. Shen, L. Zhang, B. Utama, J. Wang, Y. Gan, X. Wang, J. Wang, L. Chen, G. M. Vercellotti, J. S. Coselli, et al. Human cytomegalovirus inhibits Akt-mediated eNOS activation through upregulating PTEN (phosphatase and tensin homolog deleted on chromosome 10) Cardiovasc Res, February 1, 2006; 69(2): 502 - 511. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R-S Koskela, P Mutanen, J-A Sorsa, and M Klockars Respiratory disease and cardiovascular morbidity Occup. Environ. Med., September 1, 2005; 62(9): 650 - 655. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Andraws, J. S. Berger, and D. L. Brown Effects of Antibiotic Therapy on Outcomes of Patients With Coronary Artery Disease: A Meta-analysis of Randomized Controlled Trials JAMA, June 1, 2005; 293(21): 2641 - 2647. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. P. Cannon, E. Braunwald, C. H. McCabe, J. T. Grayston, B. Muhlestein, R. P. Giugliano, R. Cairns, A. M. Skene, and the Pravastatin or Atorvastatin Evaluation and Inf Antibiotic Treatment of Chlamydia pneumoniae after Acute Coronary Syndrome N. Engl. J. Med., April 21, 2005; 352(16): 1646 - 1654. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. S. Kruth, N. L. Jones, W. Huang, B. Zhao, I. Ishii, J. Chang, C. A. Combs, D. Malide, and W.-Y. Zhang Macropinocytosis Is the Endocytic Pathway That Mediates Macrophage Foam Cell Formation with Native Low Density Lipoprotein J. Biol. Chem., January 21, 2005; 280(3): 2352 - 2360. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. H Haralambieva, I. D Iankov, P. V Ivanova, V. Mitev, and I. G Mitov Chlamydophila pneumoniae induces p44/p42 mitogen-activated protein kinase activation in human fibroblasts through Toll-like receptor 4 J. Med. Microbiol., December 1, 2004; 53(12): 1187 - 1193. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Aburawi, P. Liuba, E. Pesonen, S. Yla-Herttuala, and S. Sjoblad Acute Respiratory Viral Infections Aggravate Arterial Endothelial Dysfunction in Children With Type 1 Diabetes Diabetes Care, November 1, 2004; 27(11): 2733 - 2735. [Full Text] [PDF]
|
|
|
|
|
|
B. R. Clapp, A. D. Hingorani, R. K. Kharbanda, V. Mohamed-Ali, J. W. Stephens, P. Vallance, and R. J. MacAllister Inflammation-induced endothelial dysfunction involves reduced nitric oxide bioavailability and increased oxidant stress Cardiovasc Res, October 1, 2004; 64(1): 172 - 178. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Khovidhunkit, M.-S. Kim, R. A. Memon, J. K. Shigenaga, A. H. Moser, K. R. Feingold, and C. Grunfeld Thematic review series: The Pathogenesis of Atherosclerosis. Effects of infection and inflammation on lipid and lipoprotein metabolism mechanisms and consequences to the host J. Lipid Res., July 1, 2004; 45(7): 1169 - 1196. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L. Price, P. S. Sharp, M. E. North, S. J. Rainbow, and S. C. Knight Advanced Glycation End Products Modulate the Maturation and Function of Peripheral Blood Dendritic Cells Diabetes, June 1, 2004; 53(6): 1452 - 1458. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. Henriksen, M. Hitt, Z. Xing, J. Wang, C. Haslett, R. A. Riemersma, D. J. Webb, Y. V. Kotelevtsev, and J.-M. Sallenave Adenoviral Gene Delivery of Elafin and Secretory Leukocyte Protease Inhibitor Attenuates NF-{kappa}B-Dependent Inflammatory Responses of Human Endothelial Cells and Macrophages to Atherogenic Stimuli J. Immunol., April 1, 2004; 172(7): 4535 - 4544. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. D. Johnson, K. E. Kip, O. C. Marroquin, P. M Ridker, S. F. Kelsey, L. J. Shaw, C. J. Pepine, B. Sharaf, C. N. Bairey Merz, G. Sopko, et al. Serum Amyloid A as a Predictor of Coronary Artery Disease and Cardiovascular Outcome in Women: The National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Circulation, February 17, 2004; 109(6): 726 - 732. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. L. Nerheim, J. L. Meier, M. A. Vasef, W.-G. Li, L. Hu, J. B. Rice, D. Gavrila, W. E. Richenbacher, and N. L. Weintraub Enhanced Cytomegalovirus Infection in Atherosclerotic Human Blood Vessels Am. J. Pathol., February 1, 2004; 164(2): 589 - 600. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. P. Gurfinkel, R. Leon de la Fuente, O. Mendiz, and B. Mautner Flu vaccination in acute coronary syndromes and planned percutaneous coronary interventions (FLUVACS) Study: One-year follow-up Eur. Heart J., January 1, 2004; 25(1): 25 - 31. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Madjid, M. Naghavi, S. Litovsky, and S. W. Casscells Influenza and Cardiovascular Disease: A New Opportunity for Prevention and the Need for Further Studies Circulation, December 2, 2003; 108(22): 2730 - 2736. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Hirono, E. Dibrov, C. Hurtado, A. Kostenuk, R. Ducas, and G. N. Pierce Chlamydia pneumoniae Stimulates Proliferation of Vascular Smooth Muscle Cells Through Induction of Endogenous Heat Shock Protein 60 Circ. Res., October 17, 2003; 93(8): 710 - 716. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Jain, E. L. Batista Jr., C. Serhan, G. L. Stahl, and T. E. Van Dyke Role for Periodontitis in the Progression of Lipid Deposition in an Animal Model Infect. Immun., October 1, 2003; 71(10): 6012 - 6018. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Khovidhunkit, A. H. Moser, J. K. Shigenaga, C. Grunfeld, and K. R. Feingold Endotoxin down-regulates ABCG5 and ABCG8 in mouse liver and ABCA1 and ABCG1 in J774 murine macrophages: differential role of LXR J. Lipid Res., September 1, 2003; 44(9): 1728 - 1736. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D Tousoulis, G Davies, C Stefanadis, P Toutouzas, and J A Ambrose Inflammatory and thrombotic mechanisms in coronary atherosclerosis Heart, September 1, 2003; 89(9): 993 - 997. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. B. Rice, L. L. Stoll, W.-G. Li, G. M. Denning, J. Weydert, E. Charipar, W. E. Richenbacher, F. J. Miller Jr, and N. L. Weintraub Low-Level Endotoxin Induces Potent Inflammatory Activation of Human Blood Vessels: Inhibition by Statins Arterioscler Thromb Vasc Biol, September 1, 2003; 23(9): 1576 - 1582. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Boekholdt, W. R.P. Agema, R. J.G. Peters, A. H. Zwinderman, E. E. van der Wall, P. H. Reitsma, J. J.P. Kastelein, and J. W. Jukema Variants of Toll-Like Receptor 4 Modify the Efficacy of Statin Therapy and the Risk of Cardiovascular Events Circulation, May 20, 2003; 107(19): 2416 - 2421. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. J. Mehta and I. A. Khan HIV-Associated Coronary Artery Disease Angiology, May 1, 2003; 54(3): 269 - 275. [Abstract] [PDF]
|
|
|
|
|
|
G. G. L. Biondi-Zoccai, A. Abbate, G. Liuzzo, and L. M. Biasucci Atherothrombosis, inflammation, and diabetes J. Am. Coll. Cardiol., April 2, 2003; 41(7): 1071 - 1077. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Zahn, S. Schneider, B. Frilling, K. Seidl, U. Tebbe, M. Weber, M. Gottwik, E. Altmann, F. Seidel, J. Rox, et al. Antibiotic Therapy After Acute Myocardial Infarction: A Prospective Randomized Study Circulation, March 11, 2003; 107(9): 1253 - 1259. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Kim, J. Shigenaga, A. Moser, K. Feingold, and C. Grunfeld Repression of Farnesoid X Receptor during the Acute Phase Response J. Biol. Chem., March 7, 2003; 278(11): 8988 - 8995. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Liuba, J. Persson, J. Luoma, S. Yla-Herttuala, and E. Pesonen Acute infections in children are accompanied by oxidative modification of LDL and decrease of HDL cholesterol, and are followed by thickening of carotid intima-media Eur. Heart J., March 2, 2003; 24(6): 515 - 521. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. V Pislaru, M. Van Ranst, C. Pislaru, Z. Szelid, G. Theilmeier, J.M Ossewaarde, P. Holvoet, S. Janssens, E. Verbeken, and F. J Van de Werf Chlamydia pneumoniae induces neointima formation in coronary arteries of normal pigs Cardiovasc Res, March 1, 2003; 57(3): 834 - 842. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Porqueddu, R. Spirito, A. Parolari, M. Zanobini, G. Pompilio, G. Polvani, F. Alamanni, D. Stangalini, E. Tremoli, and P. Biglioli Lack of Association Between Serum Immunoreactivity and Chlamydia pneumoniae Detection in the Human Aortic Wall Circulation, November 19, 2002; 106(21): 2647 - 2648. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. W. Haider, P. W. F. Wilson, M. G. Larson, J. C. Evans, E. L. Michelson, P. A. Wolf, C. J. O'Donnell, and D. Levy The association of seropositivity to Helicobacter pylori, Chlamydia pneumoniae, and cytomegalovirus with risk of cardiovascular disease: A prospective study J. Am. Coll. Cardiol., October 16, 2002; 40(8): 1408 - 1413. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Delahaye, E. P. McFadden, and G. de Gevigney The scourge of coronary disease in diabetic patients: will antibiotics sweeten the pill? Eur. Heart J., October 2, 2002; 23(20): 1557 - 1559. [Full Text] [PDF]
|
|
|
|
|
|
J.A. Erkens, O.H. Klungel, R.M.C. Herings, R.P. Stolk, J.A. Spoelstra, D.E. Grobbee, and H.G.M. Leufkens Use of fluorquinolones is associated with a reduced risk of coronary heart disease in diabetes mellitus type 2 patients Eur. Heart J., October 2, 2002; 23(20): 1575 - 1579. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Jackson, O. Yu, S. R. Heckbert, B. M. Psaty, D. Malais, W. E. Barlow, and W. W. Thompson Influenza Vaccination Is Not Associated with a Reduction in the Risk of Recurrent Coronary Events Am. J. Epidemiol., October 1, 2002; 156(7): 634 - 640. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. J. Mehta, I. A. Khan, R. N. Mehta, and R. M. Gowda Acute Coronary Syndrome in Patients with Human Immunodeficiency Virus Disease Angiology, September 1, 2002; 53(5): 545 - 549. [Abstract] [PDF]
|
|
|
|
 |
|
 S. Kiechl, P. Werner, G. Egger, F. Oberhollenzer, M. Mayr, Q. Xu, W. Poewe, and J. Willeit Active and Passive Smoking, Chronic Infections, and the Risk of Carotid Atherosclerosis: Prospective Results From the Bruneck Study Stroke, September 1, 2002; 33(9): 2170 - 2176. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. K. Hansson, P. Libby, U. Schonbeck, and Z.-Q. Yan Innate and Adaptive Immunity in the Pathogenesis of Atherosclerosis Circ. Res., August 23, 2002; 91(4): 281 - 291. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Koenig, N. Khuseyinova, M. M. Hoffmann, W. Marz, M. Frohlich, A. Hoffmeister, H. Brenner, and D. Rothenbacher CD14 C(-260)->T polymorphism, plasma levels of the soluble endotoxin receptor CD14, their association with chronic infections and risk of stable coronary artery disease J. Am. Coll. Cardiol., July 3, 2002; 40(1): 34 - 42. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. B. Sakash, G. I. Byrne, A. Lichtman, and P. Libby Cytokines Induce Indoleamine 2,3-Dioxygenase Expression in Human Atheroma-Associated Cells: Implications for Persistent Chlamydophila pneumoniae Infection Infect. Immun., July 1, 2002; 70(7): 3959 - 3961. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Tiran, H.-J. Gruber, W. F. Graier, A. H. Wagner, E. B.M. van Leeuwen, and B. Tiran Aspirin Inhibits Chlamydia pneumoniae-Induced Nuclear Factor-{kappa}B Activation, Cytokine Expression, and Bacterial Development in Human Endothelial Cells Arterioscler Thromb Vasc Biol, July 1, 2002; 22(7): 1075 - 1080. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Edfeldt, J. Swedenborg, G. K. Hansson, and Z.-q. Yan Expression of Toll-Like Receptors in Human Atherosclerotic Lesions: A Possible Pathway for Plaque Activation Circulation, March 12, 2002; 105(10): 1158 - 1161. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Libby, P. M. Ridker, and A. Maseri Inflammation and Atherosclerosis Circulation, March 5, 2002; 105(9): 1135 - 1143. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Abou-Raya, A. Naeem, H. A.-E. Kheir, and S. El Beltagy Coronary Artery Disease and Periodontal Disease: Is There a Link? Angiology, March 1, 2002; 53(2): 141 - 148. [Abstract] [PDF]
|
|
|
|
|
|
M. P. Bendeck, M. Conte, M. Zhang, N. Nili, B. H. Strauss, and S. M. Farwell Doxycycline Modulates Smooth Muscle Cell Growth, Migration, and Matrix Remodeling after Arterial Injury Am. J. Pathol., March 1, 2002; 160(3): 1089 - 1095. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Lavallee, V. Perchaud, M. Gautier-Bertrand, D. Grabli, and P. Amarenco Association Between Influenza Vaccination and Reduced Risk of Brain Infarction Stroke, February 1, 2002; 33(2): 513 - 518. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Bulut, E. Faure, L. Thomas, H. Karahashi, K. S. Michelsen, O. Equils, S. G. Morrison, R. P. Morrison, and M. Arditi Chlamydial Heat Shock Protein 60 Activates Macrophages and Endothelial Cells Through Toll-Like Receptor 4 and MD2 in a MyD88-Dependent Pathway J. Immunol., February 1, 2002; 168(3): 1435 - 1440. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C Szalai, G Fust, J Duba, J Kramer, L Romics, Z Prohaszka, and A Csaszar Association of polymorphisms and allelic combinations in the tumour necrosis factor-{alpha}-complement MHC region with coronary artery disease J. Med. Genet., January 1, 2002; 39(1): 46 - 51. [Full Text] [PDF]
|
|
|
|
|
|
X. H. Xu, P. K. Shah, E. Faure, O. Equils, L. Thomas, M. C. Fishbein, D. Luthringer, X.-P. Xu, T. B. Rajavashisth, J. Yano, et al. Toll-Like Receptor-4 Is Expressed by Macrophages in Murine and Human Lipid-Rich Atherosclerotic Plaques and Upregulated by Oxidized LDL Circulation, December 18, 2001; 104(25): 3103 - 3108. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Burian, K. Berencsi, V. Endresz, Z. Gyulai, T. Valyi-Nagy, I. Valyi-Nagy, M. Bakay, Y. Geng, D. Virok, L. Kari, et al. Chlamydia pneumoniae Exacerbates Aortic Inflammatory Foci Caused by Murine Cytomegalovirus Infection in Normocholesterolemic Mice Clin. Vaccine Immunol., November 1, 2001; 8(6): 1263 - 1266. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. George, S. Greenberg, I. Barshack, M. Singh, S. Pri-Chen, S. Laniado, and G. Keren Accelerated intimal thickening in carotid arteries of balloon-injured rats after immunization against heat shock protein 70 J. Am. Coll. Cardiol., November 1, 2001; 38(5): 1564 - 1569. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Khovidhunkit, A. H. Moser, J. K. Shigenaga, C. Grunfeld, and K. R. Feingold Regulation of scavenger receptor class B type I in hamster liver and Hep3B cells by endotoxin and cytokines J. Lipid Res., October 1, 2001; 42(10): 1636 - 1644. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Libby Current Concepts of the Pathogenesis of the Acute Coronary Syndromes Circulation, July 17, 2001; 104(3): 365 - 372. [Full Text] [PDF]
|
|
|
|
|
|
K. Yasojima, C. Schwab, E. G. McGeer, and P. L. McGeer Complement Components, but Not Complement Inhibitors, Are Upregulated in Atherosclerotic Plaques Arterioscler Thromb Vasc Biol, July 1, 2001; 21(7): 1214 - 1219. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Blankenberg, H. J. Rupprecht, C. Bickel, C. Espinola-Klein, G. Rippin, G. Hafner, M. Ossendorf, K. Steinhagen, and J. Meyer Cytomegalovirus Infection With Interleukin-6 Response Predicts Cardiac Mortality in Patients With Coronary Artery Disease Circulation, June 19, 2001; 103(24): 2915 - 2921. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Khovidhunkit, J. K. Shigenaga, A. H. Moser, K. R. Feingold, and C. Grunfeld Cholesterol efflux by acute-phase high density lipoprotein: role of lecithin:cholesterol acyltransferase J. Lipid Res., June 1, 2001; 42(6): 967 - 975. [Abstract] [Full Text]
|
|
|
|
 |
|
 C. H. Selzman, S. A. Miller, and A. H. Harken Therapeutic implications of inflammation in atherosclerotic cardiovascular disease Ann. Thorac. Surg., June 1, 2001; 71(6): 2066 - 2074. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J. Van Lenten, A. C. Wagner, D. P. Nayak, S. Hama, M. Navab, and A. M. Fogelman High-Density Lipoprotein Loses Its Anti-Inflammatory Properties During Acute Influenza A Infection Circulation, May 8, 2001; 103(18): 2283 - 2288. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Katritsis, S. Korovesis, E. Giazitzoglou, J. Parissis, P. Kalivas, M. M. Webb-Peploe, J. P.A. Ioannidis, and A. Haliassos C-Reactive Protein Concentrations and Angiographic Characteristics of Coronary Lesions Clin. Chem., May 1, 2001; 47(5): 882 - 886. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. LaBiche, D. Koziol, T. C. Quinn, C. Gaydos, S. Azhar, G. Ketron, S. Sood, and T. J. DeGraba Presence of Chlamydia pneumoniae in Human Symptomatic and Asymptomatic Carotid Atherosclerotic Plaque Stroke, April 1, 2001; 32(4): 855 - 860. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Burian, Z. Kis, D. Virok, V. Endresz, Z. Prohaszka, J. Duba, K. Berencsi, K. Boda, L. Horvath, L. Romics, et al. Independent and Joint Effects of Antibodies to Human Heat-Shock Protein 60 and Chlamydia pneumoniae Infection in the Development of Coronary Atherosclerosis Circulation, March 20, 2001; 103(11): 1503 - 1508. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Hoffmeister, D. Rothenbacher, G. Bode, K. Persson, W. Marz, M. A. Nauck, H. Brenner, V. Hombach, and W. Koenig Current Infection With Helicobacter pylori, but Not Seropositivity to Chlamydia pneumoniae or Cytomegalovirus, Is Associated With an Atherogenic, Modified Lipid Profile Arterioscler Thromb Vasc Biol, March 1, 2001; 21(3): 427 - 432. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F Schiele, M K Batur, M F Seronde, N Meneveau, P Sewoke, A Bassignot, G Couetdic, F Caulfield, and J-P Bassand Cytomegalovirus, Chlamydia pneumoniae, and Helicobacter pylori IgG antibodies and restenosis after stent implantation: an angiographic and intravascular ultrasound study Heart, March 1, 2001; 85(3): 304 - 311. [Abstract] [Full Text]
|
|
|
|
|
|
K. Yasojima, C. Schwab, E. G. McGeer, and P. L. McGeer Generation of C-Reactive Protein and Complement Components in Atherosclerotic Plaques Am. J. Pathol., March 1, 2001; 158(3): 1039 - 1051. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kiechl, G. Egger, M. Mayr, C. J. Wiedermann, E. Bonora, F. Oberhollenzer, M. Muggeo, Q. Xu, G. Wick, W. Poewe, et al. Chronic Infections and the Risk of Carotid Atherosclerosis : Prospective Results From a Large Population Study Circulation, February 27, 2001; 103(8): 1064 - 1070. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Gullestad, H. Aass, J. G. Fjeld, L. Wikeby, A. K. Andreassen, H. Ihlen, S. Simonsen, J. Kjekshus, S. Nitter-Hauge, T. Ueland, et al. Immunomodulating Therapy With Intravenous Immunoglobulin in Patients With Chronic Heart Failure Circulation, January 16, 2001; 103(2): 220 - 225. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. K. Shah Link Between Infection and Atherosclerosis: Who Are The Culprits: Viruses, Bacteria, Both, or Neither? Circulation, January 2, 2001; 103(1): 5 - 6. [Full Text] [PDF]
|
|
|
|
|
|
R. G. J. Gibbs, M. Sian, A. W. M. Mitchell, R. M. Greenhalgh, A. H. Davies, and N. Carey Chlamydia pneumoniae Does Not Influence Atherosclerotic Plaque Behavior in Patients With Established Carotid Artery Stenosis Stroke, December 1, 2000; 31(12): 2930 - 2935. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. B. Muhlestein, J. L. Anderson, J. F. Carlquist, K. Salunkhe, B. D. Horne, R. R. Pearson, T. J. Bunch, A. Allen, S. Trehan, and C. Nielson Randomized Secondary Prevention Trial of Azithromycin in Patients With Coronary Artery Disease : Primary Clinical Results of the ACADEMIC Study Circulation, October 10, 2000; 102(15): 1755 - 1760. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Espinola-Klein, H.-J. Rupprecht, S. Blankenberg, C. Bickel, H. Kopp, G. Rippin, G. Hafner, U. Pfeifer, and J. Meyer Are Morphological or Functional Changes in the Carotid Artery Wall Associated With Chlamydia pneumoniae, Helicobacter pylori, Cytomegalovirus, or Herpes Simplex Virus Infection? Stroke, September 1, 2000; 31(9): 2127 - 2133. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Fichtlscherer, G. Rosenberger, D. H. Walter, S. Breuer, S. Dimmeler, and A. M. Zeiher Elevated C-Reactive Protein Levels and Impaired Endothelial Vasoreactivity in Patients With Coronary Artery Disease Circulation, August 29, 2000; 102(9): 1000 - 1006. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. G. Alber, K. L. Powell, P. Vallance, D. A. Goodwin, and C. Grahame-Clarke Herpesvirus Infection Accelerates Atherosclerosis in the Apolipoprotein E-Deficient Mouse Circulation, August 15, 2000; 102(7): 779 - 785. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Waugh, J. Li-Hawkins, E. Yuksel, M. D. Kuo, P. N. Cifra, P. R. Hilfiker, R. Geske, M. Chawla, J. Thomas, S. M. Shenaq, et al. Thrombomodulin Overexpression to Limit Neointima Formation Circulation, July 18, 2000; 102(3): 332 - 337. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. D. Sorlie, F. J. Nieto, E. Adam, A. R. Folsom, E. Shahar, and M. Massing A Prospective Study of Cytomegalovirus, Herpes Simplex Virus 1, and Coronary Heart Disease: The Atherosclerosis Risk in Communities (ARIC) Study Arch Intern Med, July 10, 2000; 160(13): 2027 - 2032. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Liuzzo, J. J. Goronzy, H. Yang, S. L. Kopecky, D. R. Holmes, R. L. Frye, and C. M. Weyand Monoclonal T-Cell Proliferation and Plaque Instability in Acute Coronary Syndromes Circulation, June 27, 2000; 101(25): 2883 - 2888. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. K. Shah Circulating Markers of Inflammation for Vascular Risk Prediction : Are they Ready for Prime Time Circulation, April 18, 2000; 101(15): 1758 - 1759. [Full Text] [PDF]
|
|
|
|
|
|
P. M. Ridker, N. Rifai, M. J. Stampfer, and C. H. Hennekens Plasma Concentration of Interleukin-6 and the Risk of Future Myocardial Infarction Among Apparently Healthy Men Circulation, April 18, 2000; 101(15): 1767 - 1772. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J George, A Afek, B Gilburd, D Harats, and Y Shoenfeld Autoimmunity in atherosclerosis: lessons from experimental models Lupus, March 1, 2000; 9(3): 223 - 227. [Abstract] [PDF]
|
|
|
|
|
|
M. J Davies CORONARY DISEASE: The pathophysiology of acute coronary syndromes Heart, March 1, 2000; 83(3): 361 - 366. [Full Text]
|
|
|
|
|
|
J. Willeit, S. Kiechl, F. Oberhollenzer, G. Rungger, G. Egger, E. Bonora, M. Mitterer, and M. Muggeo Distinct Risk Profiles of Early and Advanced Atherosclerosis : Prospective Results From the Bruneck Study Arterioscler Thromb Vasc Biol, February 1, 2000; 20(2): 529 - 537. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Urbich, M. Fritzenwanger, A. M. Zeiher, and S. Dimmeler Laminar Shear Stress Upregulates the Complement-Inhibitory Protein Clusterin : A Novel Potent Defense Mechanism Against Complement-Induced Endothelial Cell Activation Circulation, February 1, 2000; 101(4): 352 - 355. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Roivainen, M. Viik-Kajander, T. Palosuo, P. Toivanen, M. Leinonen, P. Saikku, L. Tenkanen, V. Manninen, T. Hovi, and M. Manttari Infections, Inflammation, and the Risk of Coronary Heart Disease Circulation, January 25, 2000; 101(3): 252 - 257. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Bartels, M. Maass, G. Bein, N. Brill, J. F. M. Bechtel, R. Leyh, and H.-H. Sievers Association of Serology With the Endovascular Presence of Chlamydia pneumoniae and Cytomegalovirus in Coronary Artery and Vein Graft Disease Circulation, January 18, 2000; 101(2): 137 - 141. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Ambrose and G. Dangas Unstable Angina: Current Concepts of Pathogenesis and Treatment Arch Intern Med, January 10, 2000; 160(1): 25 - 37. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Hoffmeister, D. Rothenbacher, P. Wanner, G. Bode, K. Persson, H. Brenner, V. Hombach, and W. Koenig Seropositivity to chlamydial lipopolysaccharide and chlamydia pneumoniae, systemic inflammation and stable coronary artery disease: Negative results of a case-control study J. Am. Coll. Cardiol., January 1, 2000; 35(1): 112 - 118. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Kol, A. H. Lichtman, R. W. Finberg, P. Libby, and E. A. Kurt-Jones Cutting Edge: Heat Shock Protein (HSP) 60 Activates the Innate Immune Response: CD14 Is an Essential Receptor for HSP60 Activation of Mononuclear Cells J. Immunol., January 1, 2000; 164(1): 13 - 17. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Koenig, D. Rothenbacher, A. Hoffmeister, M. Miller, G. Bode, G. Adler, V. Hombach, W. Marz, M. B. Pepys, and H. Brenner Infection With Helicobacter pylori Is Not a Major Independent Risk Factor for Stable Coronary Heart Disease : Lack of a Role of Cytotoxin-Associated Protein A-Positive Strains and Absence of a Systemic Inflammatory Response Circulation, December 7, 1999; 100(23): 2326 - 2331. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Wiedermann, S. Kiechl, S. Dunzendorfer, P. Schratzberger, G. Egger, F. Oberhollenzer, and J. Willeit Association of endotoxemia with carotid atherosclerosis and cardiovascular disease: Prospective results from the bruneck study J. Am. Coll. Cardiol., December 1, 1999; 34(7): 1975 - 1981. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Koenig and C. Wanner C-reactive protein and coronary artery disease--what is the link? Nephrol. Dial. Transplant., December 1, 1999; 14(12): 2798 - 2800. [Full Text] [PDF]
|
|
|
|
|
|
T. Quaschning and C. Wanner The role of Chlamydia in coronary heart disease--fact or fiction? Nephrol. Dial. Transplant., December 1, 1999; 14(12): 2800 - 2803. [Full Text] [PDF]
|
|
|
|
 |
|
 P. M. Ridker, C. H. Hennekens, J. E. Buring, R. Kundsin, and J. Shih Baseline IgG Antibody Titers to Chlamydia pneumoniae, Helicobacter pylori, Herpes Simplex Virus, and Cytomegalovirus and the Risk for Cardiovascular Disease in Women Ann Intern Med, October 19, 1999; 131(8): 573 - 577. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Mallat, S. Besnard, M. Duriez, V. Deleuze, F. Emmanuel, M. F. Bureau, F. Soubrier, B. Esposito, H. Duez, C. Fievet, et al. Protective Role of Interleukin-10 in Atherosclerosis Circ. Res., October 15, 1999; 85 (8): e17 - e24. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Libby and P. M. Ridker Novel Inflammatory Markers of Coronary Risk : Theory Versus Practice Circulation, September 14, 1999; 100(11): 1148 - 1150. [Full Text] [PDF]
|
|
|
|
|
|
G. M. Chisolm III, S. L. Hazen, P. L. Fox, and M. K. Cathcart The Oxidation of Lipoproteins by Monocytes-Macrophages. BIOCHEMICAL AND BIOLOGICAL MECHANISMS J. Biol. Chem., September 10, 1999; 274(37): 25959 - 25962. [Full Text] [PDF]
|
|
|
|
 |
|
 P.-Y. Lovey, A. Morabia, D Bleed, O Péter, G Dupuis, and J Petite Long term vascular complications of Coxiella burnetii infection in Switzerland: cohort study BMJ, July 31, 1999; 319(7205): 284 - 286. [Abstract] [Full Text]
|
|
|
|
|
|
C. Zellner, T. M. Chou, V. Pasceri, A. Maseri, G. Cammarota, G. Patti, L. Cuoco, A. Gasbarrini, R. L. Grillo, G. Fedeli, et al. Antibiotic Prophylaxis and Treatment of Cardiovascular Disease • Response Circulation, April 13, 1999; 99 (14): 1922 - 1926. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||